William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the completion of the sale, the director now owns 601,233 shares in the company, valued at $27,067,509.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Hoffman also recently made the following trade(s):

• On Monday, September 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00.

Inari Medical Trading Up 1.7 %

Shares of NASDAQ NARI opened at $44.23 on Friday. The company has a market capitalization of $2.57 billion, a P/E ratio of -107.88 and a beta of 1.00. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $67.13. The stock has a 50 day moving average of $44.11 and a 200-day moving average of $45.83.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The business had revenue of $145.82 million for the quarter, compared to analyst estimates of $143.96 million. Analysts predict that Inari Medical, Inc. will post -0.7 EPS for the current fiscal year.

Institutional Trading of Inari Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S bought a new position in Inari Medical in the 1st quarter valued at about $30,000. GAMMA Investing LLC increased its stake in shares of Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the last quarter. Covestor Ltd lifted its holdings in Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after purchasing an additional 376 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after purchasing an additional 522 shares during the period. Institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Stifel Nicolaus started coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $50.00 target price on shares of Inari Medical in a report on Monday, August 26th. Leerink Partnrs upgraded Inari Medical to a “hold” rating in a research note on Tuesday, September 3rd. Wells Fargo & Company lowered their price target on Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Wednesday, October 9th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Inari Medical has an average rating of “Hold” and an average target price of $57.44.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.